& Merrifield demonstrated that their product exhibited ribonuclease activity, but their efforts to isolate a fully active product were unsuccessful. Since then, the techniques for solid-phase synthesis have continuously been improved and many effective purification techniques have been introduced. In 1989, Kent attempted synthesis of HIV-1 acid protease, a 99-residue enzyme, by applying the Boc-strategy to an improved solidphase method and, as a result of which, the product was successfully isolated as crystals [4, 51. In the solution synthesis of ribonuclease S-protein, Mercks group demonstrated that their product exhibited enzymic activity in the presence of excess S-peptide, but the amount of their final product was so small that they could not characterize it. Solution synthesis of ribonuclease A was achieved by Fujii & Yajima in 198 1 [6, 71 . They assembled the fully protected peptide from 30 segments by the azide procedure and, after deprotection followed by air-oxidation, they succeeded in isolating the product as crystals via affinity chromatography.
Since 197 1, we have been deeply involved in a project for supplying a variety of biologically active peptides to researchers for use as standards. To supply reliable peptides, we concluded that all should be synthesized by the segment condensation method in solution, with standardization of the strategy and techniques. After several trials, we designed a maximum protection strategy as follows [8, 9] :
( a ) A water-soluble carbodi-imide, 1 -ethyl-3-( 3-dimethylaminopropy1)-carbodi-imide, is used as a reagent for forming peptide bonds in the presence of HOBt or HOOBt. This procedure is better than the dicyclohexylcarbodi-imide (DCC)/HOBt or DCC/HOOBt method because the urea or acylurea formed, if any, is far more easily removable from the reaction products than when DCC is used.
( h ) Each segment is synthesized by stepwise elongation of Boc-amino acids starting from amino acid phenacyl esters: if the C'-terminus of the objective peptide has a free acid or amide, the C-terminal segment is elongated from the terminal amino acid benzyl ester or amide. The side-chain protected amino acids used are: Asp(cHx), Glu(cHx), Arg(Tos), Ser( Bzl). Thr(Bzl), Cys(MeB) or Cys(Acm), Tyr(BrZ), Lys(CIZ), His(Tos) or His( Bom) and Trp( For).
( c ) When the protected segment, Boc-peptide phenacyl ester, is used as an acid component, the terminal phenacyl ester is removed by treatment with zinc powder in acetic acid. When the segment is used as an amino component, it is treated with trifluoroacetic acid. During these deprotection reactions, all side-chain protecting groups remain intact.
( d ) After completion of all coupling reactions, the final fully protected product is deprotected by the H F method. 
Solubility of segments
In 1971, Wiinsch predicted that synthesis of peptides via maximum protection strategy is ideal, but might involve an insolubility problem when the peptide chain is elongated t o between 30 and SO residues [ 101. However, by applying the above strategy, we were able to synthesize human parathyroid hormone (PTH) having 84 residues [ l l , 121 and porcine CSa anaphylatoxin having 74 residues [ 131 without particular difficulty in solubilizing their intermediates. This showed that the solubility of the protected peptides is dependent not on the length but on the sequence. Among about 1600 fully protected segments for 120 biologically active peptides that we synthesized, more than 9Ooh were soluble in dimethylformamide (DMF), 5% were insoluble in DMF but soluble in a mixture of DMF and N-methylpyrrolidone (NMP), 3% were insoluble in NMP but soluble in a mixture of NMP and dimethylsulphoxide (DMSO), and only less than 1% were insoluble in DMSO. As has been mentioned before, fully protected segments that are synthesized following our present strategy can be used as either an amino or a carboxyl component. Such flexibility is extremely useful for avoiding insolubility problems with the products. If a product which has been synthesized by coupling several segments is found to be insoluble in suitable solvent systems for the next coupling reaction, a better solution might be discovered by altering the coupling route. One example of this is with the synthesis of a human PTH segment (39-68) [8, 91. Another example is that for the synthesis of human big-endothelin (S. Sakakibara, unpublished work): fully protected endothelin was insoluble in DMSO, but fully protected big-endothelin was soluble in a mixture of DMF and NMP. Even DMSO-insoluble segments could be solubilized in a mixture of chloroform and trifluoroethanol or hexafluoroisopropanol.
These procedures were applied to the total synthesis of angiogenin.
Total synthesis of angiogeniri
Angiogenin was first isolated by Fett ei ul. in 1985 as a tumour-derived angiogenesis factor from the human adenocarcinoma cell line , the primary structure of which is shown in Fig. 1 [ 151. Recently, the same angiogenin was found in normal human plasma [16] . This structure is highly homologous to that of human pancreatic ribonuclease A. Indeed, angiogenin possesses not only angiogenic activity in the chick embryo chorioallantoic membrane (CAM) assay [14] , and in rabbit cornea, but also has significant ribonucleolytic activities [ 17, 181. Angiogenin molecules were assembled by connecting 15 segments at the points indicated by arrows in Fig. 1 applying our present strategy. The coupling sequence of each segment is shown in Fig. 2 . During the synthesis, low solubility was encountered only with the segment 100-106. However, on further elongation with more segments, the product became more soluble and the final coupling reaction proceeded smoothly in a mixture of NMP and DMSO.
The protected peptide ( 1 -123) was treated with H F in the presence of 10% (v/v) p-cresol at -4°C for 6 0 min to remove all of the protecting groups except the Acm and For groups. The used H F was evaporated out, and then the residue was further treated with fresh H F at -4°C for 30 min in the presence of 30% (v/v) butanedithiol to remove the remaining For group. After purification by CM-cellulose chromatography followed by h.p.l.c., the product, (6 Acm)-peptide (1-123), was treated with Hg(OAc), in 5% (v/v) AcOH for 5.5 h to remove the Acm groups.
The folding conditions o f a reduced angiogenin synthesized by a recombinant DNA technology is reported to be air-oxidation for 48 h in 50 mM-Tris/HCI buffer containing 0.1 M-NaCI at pH 8.5 [19] . However, in the case of our synthetic peptide, the folding reaction proceeded smoothly when a M-solution of the reduced peptide in 0 . 1~ NH,OAc buffer at pH 8.0 was exposed to air at 5°C. Addition of reduced and oxidized glutathione to the peptide in the ratio of 100 : 10 : 1 was effective in promoting the folding reaction. The progress of the reaction was monitored by h.p.1.c. and ribonucleolytic activity. After 24 h the reaction mixture was applied o n to a reverse-phase h.p.1.c. column and the principal product was isolated as a single component. SDS/ PAGE of the product showed a single band and its molecular mass was estimated to be about 14 000 Da. Examination of the purity of the product by ion-exchange h.p.1.c. showed it to be contaminated by several side-products, although this material showed a single band on SDS/PAGE. These sideproducts may have been formed during the folding reaction at pH 8, which was probably due to deamidation of some Asn residues. This was confirmed by treating an Asncontaining segment (59-64), Asn-Lys-Asn-Gly-Asn-Pro, under the same conditions; this peptide gave several sideproducts when kept at 4°C for 22 h. Thus, the main portion of the product was purified by the same ion-exchange h.p.1.c. system. The h.p.1.c. profiles of the finally purified products are shown in Fig. 3 . Amino acid analysis after acid hydrolysis agreed well with the expected values, and that of each peak of tryptic mapping on h.p.1.c. also gave reasonable results. The angiogenic activity of the purified product was measured by CAM assay following the reported procedure [ 141. The peptide showed a significantly positive response at a dose of 5-25 ng/egg, using ten eggs as control and ten for each test solution, which agreed well with the reported values for natural angiogenin. The ribonucleolytic activity of the final product was examined by measuring the formation of acid-soluble fragments from tRNA [ 181. The activity was dose dependent and its potency at the dose of 1 pg for 4 h incubation was close to the reported value. Ribonucleolytic activity (Kca,,/K,,,) of this product was compared with that of RNAase A using a dinucleotide, CpA, as the substrate following a reported procedure [ 201 and it was found that the activity for this peptide was 5 x 105-fold lower than that for RNAase A. This ratio is similar to that reported for the natural angiogenin.
Further tests are being conducted on the angiogenic activity of our purified peptide. If it proves to display effects equivalent to the natural product for all criteria, this should enable the synthesis of a protein like angiogenin using only a combination of conventional procedures, such as segment PEPTIDE A N D PROTEIN GROUP condensation reactions in solution, removal of protecting groups in HF, folding of the deprotected molecule to obtain the native form, and purification of the final product on h.p.1.c.
Introduction
Years ago, commercially available peptide hormones were either isolated from natural origin [such as insulin and corticotropin (ACTH)] or made by classical synthesis, first by liquid-, later by solid-phase procedures. Nowadays, a further path is unlocked. With the success of the recombinant DNA techniques, peptides produced using genetic engineering (such as human growth hormone, insulin and others) have been marketed recently.
The first peptide drug made by the liquid procedure was oxytocin, introduced in 1956 by Sandoz under the trade name of Syntocinone followed by [Asn'Vals] Various accounts of large-scale peptide synthesis have been published already. At the 5th American Peptide Symposium, M. Feurer (Ciba-Geigy) [ 11 gave a lecture on special features of large-scale peptide synthesis. At the 18th European Peptide Symposium, J. Meienhofer (Hoffmann-La Roche) [2] presented a comprehensive review of the opportunities and constraints of large-scale peptide synthesis in solution and solid-phase synthesis. This account is not intended to give a comprehensive review of this subject, but Abbreviations used: ACTH, corticotropin; hCT, human calcitonin; DCCI, dicyclohexylcarbodi-imide.
to give some insight into the production of large-scale peptides in solution. Large-scale implies the production of protected amino acids in quantities of up to 6 0 kg, smaller peptides up to 30 kg, larger peptides 1-10 kg and final product up to 1 kg.
Peptides at Ciha-Geigy
The production of peptides is a very specialized section of the activities of Ciba-Geigy. At present, it has three peptide hormones on the market, namely ( Fig. 1) : Hypertensin Ciba, an octapeptide introduced in 1959, which is used for raising blood pressure; Synacthen, a tetraeicosapeptide, a lower homologue of ACTH, introduced in 1967 for use in neurological affections and rheumatoid diseases and Cibacalcin, a dotriacontapeptide, the human calcitonin, introduced in 1977, which is used in such diseases as Morbus, Paget, osteoporosis and hypercalcaemia.
Ciba-Geigy started production of peptides on a larger scale with Hypertensin in 1959. After the size of the available laboratory glass vessels was found to be inadequate, the decision was made to scale-up and so a small universal equipment unit with steel and glass-lined reactors was set up for the production of the intermediates. By the time the synthesis of Synacthen was started in 1967 and Cibacalcin in 1977, enough knowledge had been assembled in production to produce all the required intermediates on a large scale. Nevertheless, starting a new synthesis is a challenge for all involved, because many big obstacles have to be overcome.
From discovery to production
The path that must be taken to start production of a complex peptide, from the first research synthesis to large-scale production, will be illustrated using Cibacalcin as an example. All known calcitonins from different species consist of one single chain of 32 amino acids linked by peptide bonds.
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